AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02371317 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: Patients are randomized to an intervention
Study NCT02371317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care
Study NCT03943784 — intervention group
Intervention type: DRUG
Intervention: Non-Selective Beta-Blocking Agent
Description: Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
Study NCT02744833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271
Study NCT02744833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium (Lovenox®)
Study NCT00975312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple combination cream
Description: The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
Study NCT00975312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05%
Description: Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
Study NCT03118024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Solutions
Description: crystalloid restrictive anesthesia protocol
Study NCT03118024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Catecholamines
Description: catecholamine restrictive anesthesia protocol
Study NCT01936857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
Study NCT01936857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone Maintenance Therapy
Description: Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
Study NCT03115892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green Tea With Aloe Vera mouthwash
Description: measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
Study NCT03115892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: chlorohexidine mouthwash take two times per day for one week
Study NCT04475432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-03, 0.25%
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Study NCT04475432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TP-03 Vehicle
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study NCT02371317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care
Study NCT02371317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association Recommended Self-Care
Description: All Patients receive AHA Recommended Self-Care
Study NCT04384042 — intervention group
Intervention type: OTHER
Intervention: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
Description: This is an online patient-reported questionnaire that examines the presence or absence of olfactory and taste disturbances, the onset of olfactory and taste disturbances in relation to other COVID-19 symptoms, and the temporal evolution of the severity of olfactory and taste disturbances. The occurrence of ear symptoms in COVID-19 infection will also be evaluated in this questionnaire as a secondary outcome. The questionnaire will also have questions relating to the patient's underlying health conditions, risk factors for COVID-19 infection, and demographics.
Study NCT03290261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: 3 hypnosis sessions performed at 4 - 6 weeks apart
Study NCT03795961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current electrical stimulation
Description: anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
Study NCT03701984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
Study NCT03701984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
Study NCT03701984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
Study NCT00975910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
Study NCT03795961 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current electrical stimulation
Description: anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
Study NCT00823147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Induction
Description: Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
Study NCT04049162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Plus Exercise (BB-EX)
Description: Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
Study NCT04049162 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Blueberry Placebo Plus Exercise (P-EX)
Description: Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
Study NCT04357067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lingual brackets
Description: A type of bracket that applied lingual surface of teeth.
Study NCT00975910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline arm: infused at the same rate as lidocaine
Study NCT00406003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine controlled release tablet
Description: Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
Study NCT01552590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Study NCT01552590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04781738 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with no resistance warmup lasting 1-3 minutes followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment by successive stages~Six minute walk test - patients will be instructed to walk as far as possible for six minutes in a 30-meter long enclosed corridor with a flat and hard surface, marked at every meter. Meters will be calculated at the end of the test.~SF-36 is a questionnaire that contains eight domains - physical functioning (10 items); role limitations due to physical functioning (4 items); role limitations due to emotional problems (3 items); energy and vitality (4 items); mental health (5 items); social functioning (2 items); bodily pain (2 items); and general health perceptions (5 items).~Scores are summed for each domain and were transformed into scores of between 0 (worst possible health state) to 100 (best possible health state).
Study NCT00734630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebivolol
Description: Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Study NCT00734630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
Study NCT02034708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem®
Description: Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Study NCT02034708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadovist®/Gadavist®
Description: Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Study NCT01479387 — intervention group
Intervention type: DRUG
Intervention: [111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)
Description: Patients who have received In-111 Zevalin.
Study NCT03433989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: telephone interview
Description: questionnaire PDEQ et IES-R
Study NCT01925833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Both insertion and withdrawal
Description: inspection and polypectomy during both insertion and withdrawal of colonoscopy
Study NCT01925833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only withdrawal
Description: inspection and polypectomy during only withdrawal of colonoscopy
Study NCT00733980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK561679
Description: GSK561679
Study NCT00733980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02693938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Follicular Euglycemic clamp
Description: Follicular Euglycemic clamp during follicular phase
Study NCT02693938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luteal Euglycemic clamp
Description: Luteal Euglycemic clamp during luteal phase
Study NCT01922076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT01922076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01922076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01922076 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00642187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Study NCT00642187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02748187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBASP
Description: Interpersonal psychotherapy for chronic depression
Study NCT00349479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Barrier assessment / interactive educational intervention
Description: Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education.
Study NCT00180635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoguanidine
Description: 500mg
Study NCT03868449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 questions
Description: 3 questions from the AskShareKnow model
Study NCT03101943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture (FSN)
Description: The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
Study NCT03101943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Program
Description: The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
Study NCT03101943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water Delivery
Description: Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
Study NCT03101943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Delivery
Description: Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
Study NCT03857022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced External Counterpulsa
Description: The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
Study NCT02010411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin (drug)
Description: Outcomes compared to saline or no intervention in each subject.
Study NCT01519128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Digoxin
Description: Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
Study NCT01519128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: TMC278
Description: Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
Study NCT01448083 — intervention group
Intervention type: OTHER
Intervention: Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.
Description: Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
Study NCT01643369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Compassion Training
Description: Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
Study NCT01643369 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult Health Education Curriculum
Description: Eight week training in health and wellness, using a curriculum developed specifically for this study.
Study NCT01643369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Attention Training
Description: Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
Study NCT01234779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: 10 mg orally daily, 4 weeks
Study NCT01234779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: 30 mg orally daily, 4 weeks
Study NCT01234779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 15 mg orally daily, 4 weeks
Study NCT01234779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 4 weeks
Study NCT00180635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 2ml
Study NCT04259086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA for injection
Description: Intramuscular injection
Study NCT01850979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
Study NCT01850979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
Study NCT03248375 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Segmentectomy
Description: The administration of radioactivity in a branch of an artery of the liver
Study NCT04357067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labial brackets
Description: A type of bracket that applied labial surface of teeth.
Study NCT03617770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Opt-In
Description: 8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
Study NCT03617770 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: 8-week intervention that includes weekly telephone counseling on healthy living.
Study NCT01137058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-healthcare service
Description: Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
Study NCT01137058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG group
Description: Glucose control with self monitoring of blood glucose.
Study NCT01263236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally
Study NCT01263236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03064698 — intervention group
Intervention type: OTHER
Intervention: Post-partum Doppler ultrasound
Description: Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
Study NCT02528006 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Type 2 Thyroplasty using Titanium Bridges
Study NCT01665157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enimaclin®
Description: Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy.
Study NCT01665157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-controlled diet
Description: Self-controlled low residue diet.
Study NCT01665157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2L PEG-ELS
Description: Normal volume of PEG-ELS
Study NCT01665157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-ELS
Description: Normal volume of PEG-ELS